Attard, G., Greystoke, A., Kaye, S., De Bono, J. (2006) Update on tubulin-binding agents. PATHOLOGIE BIOLOGIE, 54 (2). pp. 72-84. ISSN 0369-8114

Full text not available from this repository.

Abstract

Update on tubulin-binding agents The clinical and commercial success of the taxanes and vinca alkaloids resulted in a drive to improve on current formulations and discover new compounds that target the microtubule. These strategies are all aimed at improving on (1) anti-tumour activity, (2) toxicity profile and (3) pharmacology. Drugs undergoing clinical development include the novel semi-synthetic taxane derivatives (DJ-927, XRP6258 and XRP9881), the epothilones, the dolastations, vinflunine and the combretastatin analogues. In several cases, some improvements in tumour response rates have been seen but randomised trials need to be completed before the role of specific novel tubulin-binding agents can be established. (C) 2005 Elsevier SAS. All rights reserved.

Item Type:	Review Article
Authors (ICR Faculty only):	De-Bono, Johann and Kaye, Stan
All Authors:	Attard, G., Greystoke, A., Kaye, S., De Bono, J.
Uncontrolled Keywords:	tubulin-binding; taxanes; vinca alkaloids; dolastations; vinflunine; combretastatin analogues Advanced solid tumors; metastatic breast-cancer; phase-i trial; combretastatin a4 phosphate; docosahexaenoic acid-paclitaxel; prospective randomized-trial; advanced colorectal-cancer; epothilone-b analog; cell lung-cancer; intravenous-infusion
Research teams:	ICR divisions > Cancer Therapeutics > Medicine (Kaye Drug Development Unit) ICR divisions > Clinical Studies > Medicine (Kaye Drug Development Unit) ICR divisions > Cancer Therapeutics > Cancer Biomarkers ICR divisions > Clinical Studies > Cancer Biomarkers ICR divisions > Clinical Studies > Prostate Cancer Targeted Therapy Group
Date Deposited:	10 Aug 2007 21:05
Last Modified:	11 Jul 2017 13:44
URI:	http://publications.icr.ac.uk/id/eprint/3856

Actions (login required)

View Item